Drug Profile
Research programme: complement C1 inhibitor protein - iBio
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator iBio Inc
- Class Biological proteins; Proteins; Vascular disorder therapies
- Mechanism of Action Complement C1s inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hereditary angioedema
Highest Development Phases
- Discontinued Hereditary angioedema
Most Recent Events
- 28 Feb 2023 Discontinued - Preclinical for Hereditary angioedema in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA
- 26 Mar 2013 iBio selects a recombinant C1 esterase inhibitor product candidate for clinical development for Hereditary agioedema in USA